Evidence-Based Complementary and Alternative Medicine / 2015 / Article / Tab 5

Research Article

Effects of Traditional Chinese Medicine on Chemotherapy-Induced Myelosuppression and Febrile Neutropenia in Breast Cancer Patients

Table 5

Multivariate analysis of clinicopathological variables of FN.

Variables Before propensity matching After propensity matching
OR 95% CI OR 95% CI

Age0.9850.963–1.0070.1820.9950.979–1.0140.590
Chemotherapy regimens
 111
 21.7970.585–5.5140.3060.7850.321–1.9180.595
 36.4332.612–15.8440.0000524.3042.641–7.015<0.0001
 42.5160.942–6.7210.0661.9171.035–3.5520.039
TNM stage
 I11
 II0.8950.542–1.4780.6650.9250.613–1.3960.711
 III and IV0.8970.457–1.7570.7500.6900.383–1.2440.217
Neoadjuvant chemotherapy0.7100.426–1.1840.1901.5190.916–2.5220.106
ER0.5880.289–1.1950.1420.5440.291–1.0140.055
PR1.4040.720–2.7380.3192.6311.418–4.8820.002
HER-20.8030.464–1.3910.4341.0090.622–1.6370.970
Ki670.9460.589–1.5200.8191.1820.812–1.7210.383
TCM treatment0.1660.098–0.280<0.00010.1840.122–0.279<0.0001

Chemotherapy: 1: the chemotherapy regimens contain AC/EC (Adriamycin or epirubicin, Cyclophosphamide) and CAF/CEF (Adriamycin or epirubicin, Cyclophosphamide, and 5-Fluorouracil). 2: the chemotherapy regimens contain TC (paclitaxel or docetaxel, Cyclophosphamide) and T (paclitaxel or docetaxel). 3: the chemotherapy regimens contain anthracyclines combined with paclitaxel or docetaxel: TAC/TEC (paclitaxel or docetaxel, Cyclophosphamide, and Adriamycin or epirubicin); TA/TE (paclitaxel or docetaxel, Adriamycin or epirubicin). 4: the chemotherapy regimens contain anthracyclines followed by paclitaxel or docetaxel: AC/EC (Adriamycin or epirubicin, Cyclophosphamide); CAF/CEF (Adriamycin or epirubicin, Cyclophosphamide, and 5-Fluorouracil), followed with T or TH (paclitaxel or docetaxel, Herceptin). FN: body temperature ≥38.2°C and absolute neutrophil count <0.5 × 109/L on the same day of the fever or the day after.

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.